DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics
Journal of Cell Signaling
PUBLICATIONS
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640
International Congress on Targeted Anticancer Therapies
Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement
Keystone Symposium – New Frontiers in Understanding Tumor Metabolism
Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement
Keystone Symposium – New Frontiers in Understanding Tumor Metabolism
Biomarker Analyses from Dose Escalation and Expansion Phases of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients
EORTC-NCI-AACR International Conference
